🟢 VKTX is trading 4.3% up today after initiating Phase 1 trial for new weight-loss drug VK3019

Viking Therapeutics Inc. (VKTX) is trading at $36.30 (4.3% up) today.

• The company announced the initiation of a Phase 1 clinical trial for VK3019, an investigational dual amylin and calcitonin receptor agonist designed for weight loss.
• This development expands Viking's portfolio of novel therapies in the rapidly growing obesity sector.
• The move follows a 7.54% gain on June 23, contributing to a breakout-style run for the stock.